Atezolizumab Plus Chemo Poised for EU Approval in Small Cell Lung Cancer

July 29, 2019 – The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of atezolizumab in combination with carboplatin and etoposide for the frontline treatment of patients with extensive-stage small cell lung cancer (SCLC). The positive opinion is based on findings from the phase III IMpower133 trial, in which the combination regimen significantly improved progression-free and overall survival (OS) compared with … (leggi tutto)